Inhibition of m6A mRNA modification by depletion of methyltransferases, Mettl3 and Mettl14, enhanced response to anti-PD-1 treatment in pMMR-MSI-L CRC and melanoma. This evidence concerns the gene METTL14 and colorectal carcinoma.